Table 2 Univariate analysis of genetic alterations and response to pyrotinib combined with trastuzumab (HP) treatment.
Marker | pCR no. (%) | Non-pCR no. (%) | ORa (95% CI) | Pb | Padjustedc |
|---|---|---|---|---|---|
PIK3CA | 0.00057 | 0.024 | |||
Wild type | 21 (80.8) | 5 (19.2) | |||
Mutant | 5 (26.3) | 14 (73.7) | 0.09 (0.02–0.42) | ||
TP53 | 0.704 | 1.000 | |||
Wild type | 4 (50.0) | 4 (50.0) | |||
Mutant | 22 (59.5) | 15 (40.5) | 1.45 (0.23–9.15) | ||
ERBB2 | 1.000 | 1.000 | |||
Wild type | 24 (58.5) | 17 (41.5) | |||
Mutant | 2 (50.0) | 2 (50.0) | 0.71 (0.05–10.75) | ||
NF1 | 0.627 | 1.000 | |||
Wild type | 23 (56.1) | 18 (43.9) | |||
Mutant | 3 (75.0) | 1 (25.0) | 2.31 (0.17–129.9) | ||
NBN | 0.627 | 1.000 | |||
Wild type | 23 (56.1) | 18 (43.9) | |||
Mutant | 3 (75.0) | 1 (25.0) | 2.31 (0.17–129.9) | ||
ATRX | 1.000 | 1.000 | |||
Wild type | 24 (58.5) | 17 (41.5) | |||
Mutant | 2 (50.0) | 2 (50.0) | 0.71 (0.05–10.75) | ||
MYC | 0.010 | 0.183 | |||
Neutral | 24 (68.6) | 11 (31.4) | |||
Amplification | 2 (20.0) | 8 (80.0) | 0.12 (0.01–0.74) | ||
ERBB2 | 0.734 | 1.000 | |||
Neutral | 6 (50.0) | 6 (50.0) | |||
Amplification | 20 (60.6) | 13 (39.4) | 1.52 (0.33–7.14) | ||
CDK12 | 0.686 | 1.000 | |||
Neutral | 23 (59.0) | 16 (41.0) | |||
Amplification | 3 (50.0) | 3 (50.0) | 0.70 (0.08–5.92) | ||
CCND1 | 0.069 | 0.412 | |||
Neutral | 1 (16.7) | 5 (83.3) | |||
Amplification | 25 (64.1) | 14 (35.9) | 0.12 (0.002–1.20) | ||
ZNF217 | 1.000 | 1.000 | |||
Neutral | 22 (56.4) | 17 (43.6) | |||
Amplification | 4 (66.7) | 2 (33.3) | 1.53 (0.19–18.81) |
